SCHEMBL1984014

SCHEMBL1984014

C=CC[C]1CNCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3448145 0.72
SCHEMBL2109441 0.71
SCHEMBL3152779 0.71
SCHEMBL3143810 0.68
SCHEMBL2199290 0.68
SCHEMBL1992561 0.67
SCHEMBL16877108 0.67 GBA1 (0.31)
SCHEMBL20520815 0.67
SCHEMBL22608840 0.67
SCHEMBL271887 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117241669-A Cyclopropylamide compounds against parasites in fish 英特威国际有限公司荷兰疫苗厂 2023-12-15 CN claimed
US-20230242533-A9 SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2023-08-03 US claimed
CN-111372931-B Heterocyclic compounds as protein kinase inhibitors 怡诺安有限公司 2023-03-24 CN claimed
EP-3849968-B1 1H-INDAZOLE CARBOXAMIDES AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS (RIPK1) BRISTOL MYERS SQUIBB CO (US) 2022-12-21 EP claimed
EP-4027994-A1 KDM INHIBITORS AND USES THEREOF Dana-Farber Cancer Institute, Inc. (US) 2022-07-20 EP claimed
EP-3997087-A1 SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2022-05-18 EP claimed
EP-3849968-A1 1H-INDAZOLE CARBOXAMIDES AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS (RIPK1) Bristol-Myers Squibb Company (US) 2021-07-21 EP claimed
WO-2021050702-A1 KDM INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-03-18 WO claimed
WO-2020259601-A1 SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF IMPACT THERAPEUTICS, INC (CN) 2020-12-30 WO claimed
WO-2020056072-A1 1H-INDAZOLE CARBOXAMIDES AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS (RIPK1) BRISTOL-MYERS SQUIBB COMPANY (US) 2020-03-19 WO claimed
WO-2004099192-A2 HETEROCYCLE SUBSTITUTED CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B THE INSTITUTES OF PHARMACEUTICAL DISCOVERY, LLC (US) 2004-11-18 WO claimed
US-6803381-B1 METABOTROPIC GLUTAMATE RECEPTOR MODULATORS, ACTING AS ANTAGONISTS OR AGONISTS HOFFMANN-LA ROCHE INC. 2004-10-12 US claimed
US-20040067950-A1 High affinity ligands for nociceptin receptor ORL-1 SCHERING-PLOUGH CORPORATION 2004-04-08 US claimed
CN-1118467-C 1,3,8-triaza-spiro [4,5] decan-4-on derivatives HOFFMANN LA ROCHE (CH) 2003-08-20 CN claimed
CN-1389203-A Method for treating hair-dropping using thyromimetic compound PFIZER PROD INC (US) 2003-01-08 CN claimed
US-20020091150-A1 Carbamic acid derivatives BLEICHER KONRAD (DE) 2002-07-11 US claimed
EP-1171423-A1 CARBAMIC ACID DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2002-01-16 EP claimed
WO-2000063166-A1 CARBAMIC ACID DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2000-10-26 WO claimed
EP-0921125-A1 1,3,8-Triaza-spiro 4,5 decan-4-on derivatives F. HOFFMANN-LA ROCHE AG (CH) 1999-06-09 EP claimed
US-5536700-A Herbicidal compositions comprising aryl-5-haloalkylpyrazoles and glyphosate, it's salts, diquat or paraquat MONSANTO COMPANY (US) 1996-07-16 US claimed